Drug Profile
Glycyrrhiza/phosphatidylcholine - Pharmstandard
Alternative Names: Glycyrrhiza/phospholipids-Pharmstandard; Glycyrrhizic acid/phosphatidylcholine; Phosphatidylcholine/glycyrrhiza; Phosphatidylcholine/glycyrrhizic acid; Phosphogliv; Phospholipids/glycyrrhiza-PharmstandardLatest Information Update: 31 Mar 2011
Price :
$50
*
At a glance
- Originator Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
- Developer Pharmstandard
- Class Anti-inflammatories; Antivirals; Hepatoprotectants; Phosphatidylcholines; Phospholipids; Triterpenes
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Lipid metabolism disorders; Liver disorders
Most Recent Events
- 31 Dec 2005 Launched for Lipid metabolism disorders in Russia during 2005 (PO)
- 31 Dec 2005 Launched for Liver disorders in Russia during 2005 (PO)